6 research outputs found
Combined <i>FGFR3</i> and <i>TP53</i> mutation frequencies according to the stage/grade group.
<p>Proportion of tumours with both <i>FGFR3</i> and <i>TP53</i> mutations (orange), with <i>FGFR3</i> mutations and wild-type <i>TP53 wild-type</i> (grey), with wild-type <i>FGFR3</i> and mutated <i>TP53</i> (purple), or with wild-type <i>FGFR3</i> and wild-type <i>TP53</i> (blue), as a function of stage/grade. The number of cases in each subgroup is indicated in the corresponding rectangle.</p
PRISMA 2009 flow diagram of the study selection process.
<p>PRISMA 2009 flow diagram of the study selection process.</p
<i>TP53</i> mutation rates in <i>FGFR3</i>-wild-type and FGFR3-mutated tumours, according to a combination of stage and grade.
<p><i>TP53</i> mutation rates in <i>FGFR3</i>-wild-type and FGFR3-mutated tumours, according to a combination of stage and grade.</p
Association between <i>FGFR3</i> and <i>TP53</i> mutations according to stage and grade.
<p>ORa = odds ratio estimate.</p
Association between <i>FGFR3</i> and <i>TP53</i> mutations according to the stage/grade group.
<p>Association between <i>FGFR3</i> and <i>TP53</i> mutations according to the stage/grade group.</p
Combined <i>FGFR3</i> and <i>TP53</i> mutation frequencies by stage (pT).
<p>Proportion of tumours with both <i>FGFR3</i> and <i>TP53</i> mutations (orange), with mutated <i>FGFR3</i> and wild-type <i>TP53</i> (grey), with wild-type <i>FGFR3</i> and mutated <i>TP53</i> (purple), or with wild-type <i>FGFR3</i> and wild-type <i>TP53</i> (blue), as a function of pathological stage. The number of cases in each subgroup is indicated in the corresponding rectangle.</p